Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Simulations Plus (SLP) due to higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2] Earnings Expectations - Simulations Plus is expected to report quarterly earnings of $0.26 per share, reflecting a year-over-year increase of +36.8% [3] - Revenues are projected to be $19.5 million, which is a 5.2% increase from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 22.86% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Simulations Plus is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -19.23% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with positive readings being more predictive of earnings beats [9][10] - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically produced positive surprises nearly 70% of the time [10] Historical Performance - In the last reported quarter, Simulations Plus exceeded expectations by delivering earnings of $0.31 per share against an expected $0.25, resulting in a surprise of +24.00% [13] - Over the past four quarters, the company has beaten consensus EPS estimates three times [14] Conclusion - Simulations Plus does not currently appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Nurix Therapeutics, Inc. (NRIX) due to higher revenues, with a focus on how actual results will compare to estimates [1][3]. Earnings Expectations - The consensus estimate predicts a quarterly loss of $0.70 per share, reflecting a year-over-year change of +1.4% [3][19]. - Expected revenues are $19.81 million, which represents a significant increase of 63.9% from the same quarter last year [3][19]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4][19]. - The Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.74%, suggesting a bullish outlook from analysts [12][19]. Earnings Surprise Potential - A positive Earnings ESP reading indicates a higher likelihood of an earnings beat, especially when combined with a Zacks Rank of 2 (Buy) [10][12]. - Nurix Therapeutics has a Zacks Rank of 2, enhancing the probability of surpassing the consensus EPS estimate [12][20]. Historical Performance - In the last reported quarter, Nurix Therapeutics was expected to post a loss of $0.72 per share but actually reported a loss of -$0.67, resulting in a surprise of +6.94% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14].

Group 1 - Radius Recycling reported a quarterly loss of $0.39 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.87, representing an earnings surprise of +55.17% [1] - The company posted revenues of $726.99 million for the quarter ended May 2025, exceeding the Zacks Consensus Estimate by 7.38% and showing an increase from $673.92 million year-over-year [2] - Radius Recycling shares have increased approximately 95.1% since the beginning of the year, outperforming the S&P 500's gain of 5.5% [3] Group 2 - The earnings outlook for Radius Recycling is mixed, with the current consensus EPS estimate for the coming quarter at -$0.56 on revenues of $663 million, and -$3.84 on revenues of $2.62 billion for the current fiscal year [7] - The Zacks Industry Rank indicates that the Waste Removal Services sector is currently in the bottom 30% of over 250 Zacks industries, which may impact the stock's performance [8]

Core Viewpoint - Amphenol (APH) has shown strong stock performance, with an 8.6% increase over the past month and a 40.6% gain since the start of the year, outperforming both the Zacks Computer and Technology sector and the Zacks Electronics - Connectors industry [1] Financial Performance - Amphenol has consistently beaten earnings estimates, reporting EPS of $0.63 against a consensus estimate of $0.52 in its last earnings report, with a revenue beat of 13.93% [2] - For the current fiscal year, Amphenol is projected to achieve earnings of $2.68 per share on revenues of $20.14 billion, reflecting a 41.8% increase in EPS and a 32.33% increase in revenues [3] - The next fiscal year forecasts earnings of $2.91 per share on revenues of $21.46 billion, indicating year-over-year changes of 8.84% and 6.55%, respectively [3] Valuation Metrics - Amphenol's current trading metrics show a P/E ratio of 36.5X for the current fiscal year, which is above the peer industry average of 33.5X, and a trailing cash flow basis of 39.9X compared to the peer group's average of 13X [7] - The stock has a PEG ratio of 2.23, which does not place it among the top value stocks [7] Zacks Rank and Style Scores - Amphenol holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [8] - The stock has a Value Score of C, a Growth Score of B, and a Momentum Score of C, resulting in a combined VGM Score of B [6][8]

Core Insights - Walgreens Boots Alliance (WBA) reported revenue of $38.99 billion for the quarter ended May 2025, marking a year-over-year increase of 7.3% [1] - The earnings per share (EPS) for the same period was $0.38, down from $0.63 a year ago, but exceeded the consensus EPS estimate of $0.34 by 11.76% [1] - The reported revenue surpassed the Zacks Consensus Estimate of $36.61 billion by 6.49% [1] Revenue Breakdown - U.S. Retail Pharmacy revenues reached $30.72 billion, exceeding the average estimate of $28.76 billion by analysts, reflecting a year-over-year change of 7.8% [4] - U.S. Healthcare revenues were reported at $2.10 billion, slightly below the estimated $2.17 billion, representing a year-over-year decline of 1.1% [4] - International revenues amounted to $6.17 billion, surpassing the average estimate of $5.74 billion, with a year-over-year increase of 7.8% [4] Operating Income Analysis - Adjusted operating income for U.S. Retail Pharmacy was $350 million, significantly higher than the average estimate of $113.67 million [4] - Adjusted operating loss for Corporate and Other was reported at -$60 million, compared to the average estimate of -$52.50 million [4] - Adjusted operating income for U.S. Healthcare was $54 million, below the average estimate of $72.85 million [4] - Adjusted operating income for International was $214 million, exceeding the average estimate of $196.39 million [4] Stock Performance - Walgreens shares have returned +1.1% over the past month, while the Zacks S&P 500 composite increased by +5.1% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Investment Rating - The report indicates a strong performance in the Asia EM equity strategy, particularly highlighting Japan's earnings as a standout with a net beat ratio of +25 percentage points [2][7]. Core Insights - The earnings results for 1Q25 showed a strong performance across the Asia EM region, with Japan leading at +23.3%, followed by Korea (+20.3%), Singapore (+11.9%), and Thailand (+10.5%) [2][3][26]. - Emerging Markets (EM) overall reported a moderate earnings beat of +4.7%, while Asia Pacific ex-Japan (APxJ) saw a slightly higher beat of +6.0% [2][12]. - The report notes that the strong earnings in Japan are attributed to corporate and consumer activities that were brought forward ahead of tariff announcements in early April [1]. Summary by Region - Japan reported a remarkable earnings surprise of +23.3% with a net beat ratio of 25%, marking the second consecutive quarter of strong performance [7][26]. - Korea and Singapore also performed well, with earnings surprises of +20.3% and +11.9% respectively, while Thailand reported +10.5% [3][26]. - In contrast, Brazil experienced significant misses with an earnings surprise of -7.8%, and Turkey reported a substantial decline of -29.1% [3][26]. Summary by Sector - Major sectors showing strong earnings beats include Industrials (+16.6%), Communication Services (+11.6%), and Health Care (+10.3%) [4][32]. - Consumer Staples and Materials sectors reported slight misses, with Consumer Staples at -1.6% and Materials at -1.1% [4][32]. - The Capital Goods and Telecom Services industries were particularly strong, with earnings surprises of +24.4% and +21.5% respectively [4][32]. Stock-Level Surprises - The report highlights key stock-level surprises, focusing on companies rated Overweight (OW) that are expected to see increases in 12-month consensus estimates following strong earnings beats [5]. - Conversely, Underweight (UW) rated companies are anticipated to experience downgrades due to earnings misses [5]. Revenue Surprises - Revenue results across the region showed slight beats, with EM at +1.3%, APxJ at +1.1%, and Japan slightly missing at -0.1% [2][3]. - The report emphasizes that revenue surprises were generally positive, contributing to the overall strong earnings performance in the region [2][3].

Company Overview - McCormick (MKC) is expected to report quarterly earnings of $0.65 per share, reflecting a year-over-year decline of 5.8% [3] - Revenues are anticipated to be $1.66 billion, which is a 1.2% increase from the previous year [3] Earnings Expectations - Wall Street anticipates a year-over-year decline in earnings despite higher revenues, indicating a focus on how actual results compare to estimates [1] - The consensus EPS estimate has been revised down by 0.11% over the last 30 days, suggesting a bearish sentiment among analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for McCormick is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.19%, indicating a challenging outlook for beating estimates [12] - The stock currently holds a Zacks Rank of 4 (Sell), complicating predictions for an earnings beat [12] Historical Performance - In the last reported quarter, McCormick was expected to post earnings of $0.64 per share but delivered only $0.60, resulting in a surprise of -6.25% [13] - Over the past four quarters, McCormick has beaten consensus EPS estimates three times [14] Industry Context - General Mills (GIS), a competitor in the Zacks Food - Miscellaneous industry, is expected to report earnings of $0.71 per share, reflecting a significant year-over-year decline of 29.7% [19] - General Mills has an Earnings ESP of 0.80% but also holds a Zacks Rank of 4 (Sell), making predictions for an earnings beat difficult [20]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for General Mills due to lower revenues, with the actual results being crucial for near-term stock price movements [1][2]. Earnings Expectations - General Mills is expected to report quarterly earnings of $0.71 per share, reflecting a year-over-year decrease of 29.7%, with revenues projected at $4.6 billion, down 2.4% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.44% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. Earnings Surprise Prediction - The Most Accurate Estimate for General Mills is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.80%. However, the stock has a Zacks Rank of 4, complicating predictions of an earnings beat [12]. Historical Performance - General Mills has consistently beaten consensus EPS estimates in the past four quarters, with a notable surprise of +5.26% in the last reported quarter [13][14]. Market Reaction Factors - An earnings beat or miss may not solely dictate stock price movements, as other factors can influence investor sentiment [15]. Investment Considerations - While General Mills may not appear as a strong candidate for an earnings beat, investors should consider additional factors before making investment decisions [17].

The market expects Carnival (CCL) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended May 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the st ...

Core Insights - GameStop (GME) and United Natural Foods (UNFI) reported strong quarterly earnings but experienced significant stock declines post-reporting, with GME down over 20% and UNFI down over 15% [1][2] GameStop (GME) - GameStop's Q1 earnings were $0.17 per share, exceeding expectations of $0.07 and improving from an adjusted loss of -$0.12 per share a year ago [5] - The company's Selling, General, and Administrative Expenses (SG&A) decreased by 25% year-over-year to $228.1 million from $295.1 million [5] - Despite the positive earnings report, the stock fell due to a $1.75 billion convertible note offering, raising concerns about potential share dilution [2] - Future earnings projections for GameStop indicate a 127% increase in FY26 to $0.75 per share, although FY27 EPS is expected to decline to $0.36 [8] United Natural Foods (UNFI) - United Natural Foods reported Q3 EPS of $0.44, surpassing estimates of $0.24 by 83% and increasing 340% from $0.10 in the same quarter last year [6] - The company attributed its performance to improved efficiency across 20 distribution centers and the addition of profitable contracts [6] - UNFI reaffirmed its full-year EPS guidance of $0.70-$0.90, with projections for FY25 EPS at $0.80, up from $0.14 in FY24, and a further increase to $1.35 in FY26 [9][10] - The stock's decline was influenced by concerns over a recent cyberattack disrupting operations [2] Market Sentiment - Both companies currently hold a Zacks Rank 3 (Hold), indicating a cautious outlook despite improved operational performance [10] - The trend of EPS revisions will be critical for investors, as both stocks are trading at slight premiums to the S&P 500's forward earnings multiple of 23.3X [10][11]